SGMOQ

SEC source: 0001209191-20-013233 · doc4.xml · derivative · entry 2

Duraibabu Prathyusha · CIK 0001779092 · VP Principal Acct. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,000

Underlying: Common Stock · 33,000 shares

Expires 2030-02-02

F3 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the February 25, 2020 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.

SEC source: 0001209191-20-013233 · doc4.xml · nonDerivative · entry 1

Duraibabu Prathyusha · CIK 0001779092 · VP Principal Acct. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,250

F1 · shares: Represents 16,500 shares subject to restricted stock units granted on February 25, 2020 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates.

F2 · balance_after: Includes 2,000 shares acquired by the Reporting Person on October 31, 2019 under the Issuer's 2010 Employee Stock Purchase Plan, as amended.

SEC source: 0001209191-20-013232 · doc4.xml · derivative · entry 3

Ramelmeier Rolf Andrew · CIK 0001789340 · EVP, Technical Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,000

Underlying: Common Stock · 110,000 shares

Expires 2030-02-24

F4 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the February 25, 2020 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.

SEC source: 0001209191-20-013232 · doc4.xml · nonDerivative · entry 2

Ramelmeier Rolf Andrew · CIK 0001789340 · EVP, Technical Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,128

F3 · shares: Represents 55,000 shares subject to restricted stock units granted on February 25, 2020 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates.

SEC source: 0001209191-20-013232 · doc4.xml · nonDerivative · entry 1

Ramelmeier Rolf Andrew · CIK 0001789340 · EVP, Technical Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,128

F1 · shares: Represents shares underlying the portion of the Restricted Stock Unit that vested on February 25, 2020 surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on February 25, 2020 of $6.80/share, pursuant to the terms of the Issuer's 2018 Equity Incentive Plan.

F2 · balance_after: Includes 61 shares acquired by the Reporting Person on October 31, 2019 under the Issuer's 2010 Employee Stock Purchase Plan, as amended. Also included in this total are 2,464 shares resulting from the February 25, 2020 vesting of Reporting Person's February 25, 2019 restricted stock unit grant and 8,333 shares subject to such restricted stock unit grant that will vest in two remaining annual installments on February 25, 2021 and February 25, 2022, resulting in such restricted stock unit grant being vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date.

SEC source: 0001209191-20-013231 · doc4.xml · derivative · entry 2

LOEB GARY · CIK 0001561733 · EVP, General Counsel & Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2030-02-24

F2 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the February 25, 2020 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.

SEC source: 0001209191-20-013231 · doc4.xml · nonDerivative · entry 1

LOEB GARY · CIK 0001561733 · EVP, General Counsel & Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

F1 · shares: Represents 50,000 shares subject to restricted stock units granted on February 25, 2020 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates.

SEC source: 0001209191-20-013229 · doc4.xml · derivative · entry 3

Boissel Stephane · CIK 0001755198 · EVP, Corp. Strategy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,000

Underlying: Common Stock · 110,000 shares

Expires 2030-02-24

F4 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the February 25, 2020 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such vesting date.

SEC source: 0001209191-20-013229 · doc4.xml · nonDerivative · entry 2

Boissel Stephane · CIK 0001755198 · EVP, Corp. Strategy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,116

F3 · shares: Represents 55,000 shares subject to restricted stock units granted on February 25, 2020 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates.

SEC source: 0001209191-20-013229 · doc4.xml · nonDerivative · entry 1

Boissel Stephane · CIK 0001755198 · EVP, Corp. Strategy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,116

F1 · shares: Represents shares underlying the portion of the restricted stock unit grant that vested on February 25, 2020 surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on February 25, 2020 of $6.80/share, pursuant to the terms of the Issuer's 2018 Equity Incentive Plan.

F2 · balance_after: Includes 3,449 shares resulting from the February 25, 2020 vesting of Reporting Person's February 25, 2019 restricted stock unit grant and 11,667 shares subject to such restricted stock unit grant that will vest in two remaining annual installments on February 25, 2021 and February 25, 2022, resulting in such restricted stock unit grant being vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates.

SEC source: 0001209191-20-013228 · doc4.xml · derivative · entry 3

Macrae Sandy · CIK 0001675687 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 337,500

Underlying: Common Stock · 337,500 shares

Expires 2030-02-24

F4 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the February 25, 2020 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such vesting date.

SEC source: 0001209191-20-013228 · doc4.xml · nonDerivative · entry 2

Macrae Sandy · CIK 0001675687 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 247,979

F3 · shares: Represents 168,750 shares subject to restricted stock units granted on February 25, 2020 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates.

SEC source: 0001209191-20-013228 · doc4.xml · nonDerivative · entry 1

Macrae Sandy · CIK 0001675687 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,229

F1 · shares: Represents shares underlying the portion of the restricted stock unit grant that vested on February 25, 2020 surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on February 25, 2020 of $6.80/share, pursuant to the terms of the Issuer's 2018 Equity Incentive Plan.

F2 · balance_after: Includes 13,818 shares resulting from the February 25, 2020 vesting of Reporting Person's February 25, 2019 restricted stock unit grant and 42,168 shares subject to such restricted stock unit grant that will vest in two remaining annual installments on February 25, 2021 and February 25, 2022, resulting in such restricted stock unit grant being vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates. Additionally, this amount includes 10,500 shares subject to restricted stock units granted on January 24, 2018 which reflects the final installment of such grant that will vest on January 24, 2021, subject to the Reporting Person's continued service with the Issuer through such date.

SEC source: 0001209191-20-013315 · doc4a.xml · derivative · entry 2

LOEB GARY · CIK 0001561733 · EVP, General Counsel & Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2030-02-24

F2 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the February 25, 2020 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.

SEC source: 0001209191-20-013315 · doc4a.xml · nonDerivative · entry 1

LOEB GARY · CIK 0001561733 · EVP, General Counsel & Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

F1 · shares: Represents 50,000 shares subject to restricted stock units granted on February 25, 2020 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates.

SEC source: 0001209191-20-013311 · doc4.xml · derivative · entry 2

Woolfson Adrian · CIK 0001765497 · EVP Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2030-02-24

F2 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the February 25, 2020 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.

SEC source: 0001209191-20-013311 · doc4.xml · nonDerivative · entry 1

Woolfson Adrian · CIK 0001765497 · EVP Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

F1 · shares: Represents 50,000 shares subject to restricted stock units granted on February 25, 2020 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates.

SEC source: 0001209191-20-009453 · doc4.xml · derivative · entry 2

Markels John · CIK 0001803424 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2030-02-10

F2 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of Directors of the Issuer. The shares subject to the option vest in 36 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 36-month period measured from the grant date.

SEC source: 0001209191-20-009453 · doc4.xml · nonDerivative · entry 1

Markels John · CIK 0001803424 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will vest with respect to 1/3rd of the shares in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.

SEC source: 0001209191-20-005247 · doc4.xml · nonDerivative · entry 1

Macrae Sandy · CIK 0001675687 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,493

F1 · shares: Represents shares underlying the portion of the restricted stock unit grant that vested on January 24, 2020 surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on January 24, 2020 of $7.50/share, pursuant to the terms of the Issuer's 2013 Stock Incentive Plan.

F2 · balance_after: Includes 6,217 shares resulting from the January 24, 2020 vesting of Reporting Person's January 24, 2018 restricted stock unit grant and 10,500 shares subject to such restricted stock unit grant that will vest on January 24, 2021 resulting in such restricted stock unit grant being vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. Additionally, this amount includes 63,250 shares subject to restricted stock units granted on February 25, 2019 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates.

SEC source: 0001209191-19-058104 · doc4.xml · derivative · entry 2

Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 262,000

Underlying: Common Stock · 262,000 shares

Expires 2029-11-24

F2 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the November 25, 2019 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.

SEC source: 0001209191-19-058104 · doc4.xml · nonDerivative · entry 1

Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,750

F1 · shares: Includes 43,750 shares of common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person on November 25, 2019. The RSUs will vest with respect to 1/3rd of the shares in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's continued service with the Issuer through such date.

SEC source: 0001209191-19-058100 · doc4.xml · derivative · entry 2

Meyers James R · CIK 0001387521 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2029-11-21

F2 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of Directors of the Issuer. The shares subject to the option vest in 36 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 36-month period measured from the grant date.

SEC source: 0001209191-19-058100 · doc4.xml · nonDerivative · entry 1

Meyers James R · CIK 0001387521 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will vest with respect to 1/3rd of the shares in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.

SEC source: 0001209191-20-006107 · doc4.xml · derivative · entry 1

LOEB GARY · CIK 0001561733 · EVP, General Counsel & Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2029-08-22

F1 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the August 23, 2019 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.

SEC source: 0001209191-19-045963 · doc4.xml · derivative · entry 3

Boissel Stephane · CIK 0001755198 · EVP, Corp. Strat. & Int. CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3

Underlying: Common Stock · 11,137 shares

Expires 2021-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) ("Sangamo France"), the Reporting Person was granted the right to sell to the Issuer up to 238,100 "free shares" of Sangamo France (the "Subject Free Shares") for cash in four separate tranches beginning July 4, 2019 (the "Free Shares Put Options"). The exercise price per Subject Free Share to be paid by the Issuer upon the Reporting Person's exercise of its Free Shares Put Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Reporting Person notifies the Issuer of its exercise of its Free Shares Put Options (as converted to euros) divided by 12.8329. On August 12, 2019, the Reporting Person exercised his Free Shares Put Option with respect to the first tranche of Subject Free Shares (SEE FOOTNOTE (2) FOR CONTINUATION OF EXPLANATION)

F2 · derivative.exercise_price: (or 52,700 Subject Free Shares) (the "First Tranche Shares") in exchange for a cash payment of 111,724 euros, or approximately 2.12 euros per First Tranche Share. The Reporting Person's exercise of his Free Shares Put Option with respect to the First Tranche Shares for cash is deemed, for reporting purposes, to involve the conversion of the First Tranche Shares into shares of the Issuer's common stock and the simultaneous disposition of such common stock to the Issuer for cash. The August 12, 2019 euro to U.S. dollar exchange rate of 1.1194 was used for purposes of reporting the exercise price and the number of shares of the Issuer's common stock that was deemed to have been acquired and simultaneously disposed of by the Reporting Person upon exercise.

F1 · derivative.underlying_shares: In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) ("Sangamo France"), the Reporting Person was granted the right to sell to the Issuer up to 238,100 "free shares" of Sangamo France (the "Subject Free Shares") for cash in four separate tranches beginning July 4, 2019 (the "Free Shares Put Options"). The exercise price per Subject Free Share to be paid by the Issuer upon the Reporting Person's exercise of its Free Shares Put Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Reporting Person notifies the Issuer of its exercise of its Free Shares Put Options (as converted to euros) divided by 12.8329. On August 12, 2019, the Reporting Person exercised his Free Shares Put Option with respect to the first tranche of Subject Free Shares (SEE FOOTNOTE (2) FOR CONTINUATION OF EXPLANATION)

F2 · derivative.underlying_shares: (or 52,700 Subject Free Shares) (the "First Tranche Shares") in exchange for a cash payment of 111,724 euros, or approximately 2.12 euros per First Tranche Share. The Reporting Person's exercise of his Free Shares Put Option with respect to the First Tranche Shares for cash is deemed, for reporting purposes, to involve the conversion of the First Tranche Shares into shares of the Issuer's common stock and the simultaneous disposition of such common stock to the Issuer for cash. The August 12, 2019 euro to U.S. dollar exchange rate of 1.1194 was used for purposes of reporting the exercise price and the number of shares of the Issuer's common stock that was deemed to have been acquired and simultaneously disposed of by the Reporting Person upon exercise.

SEC source: 0001209191-19-045963 · doc4.xml · nonDerivative · entry 2

Boissel Stephane · CIK 0001755198 · EVP, Corp. Strat. & Int. CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

F1 · shares: In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) ("Sangamo France"), the Reporting Person was granted the right to sell to the Issuer up to 238,100 "free shares" of Sangamo France (the "Subject Free Shares") for cash in four separate tranches beginning July 4, 2019 (the "Free Shares Put Options"). The exercise price per Subject Free Share to be paid by the Issuer upon the Reporting Person's exercise of its Free Shares Put Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Reporting Person notifies the Issuer of its exercise of its Free Shares Put Options (as converted to euros) divided by 12.8329. On August 12, 2019, the Reporting Person exercised his Free Shares Put Option with respect to the first tranche of Subject Free Shares (SEE FOOTNOTE (2) FOR CONTINUATION OF EXPLANATION)

F2 · shares: (or 52,700 Subject Free Shares) (the "First Tranche Shares") in exchange for a cash payment of 111,724 euros, or approximately 2.12 euros per First Tranche Share. The Reporting Person's exercise of his Free Shares Put Option with respect to the First Tranche Shares for cash is deemed, for reporting purposes, to involve the conversion of the First Tranche Shares into shares of the Issuer's common stock and the simultaneous disposition of such common stock to the Issuer for cash. The August 12, 2019 euro to U.S. dollar exchange rate of 1.1194 was used for purposes of reporting the exercise price and the number of shares of the Issuer's common stock that was deemed to have been acquired and simultaneously disposed of by the Reporting Person upon exercise.

SEC source: 0001209191-19-045963 · doc4.xml · nonDerivative · entry 1

Boissel Stephane · CIK 0001755198 · EVP, Corp. Strat. & Int. CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,637

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) ("Sangamo France"), the Reporting Person was granted the right to sell to the Issuer up to 238,100 "free shares" of Sangamo France (the "Subject Free Shares") for cash in four separate tranches beginning July 4, 2019 (the "Free Shares Put Options"). The exercise price per Subject Free Share to be paid by the Issuer upon the Reporting Person's exercise of its Free Shares Put Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Reporting Person notifies the Issuer of its exercise of its Free Shares Put Options (as converted to euros) divided by 12.8329. On August 12, 2019, the Reporting Person exercised his Free Shares Put Option with respect to the first tranche of Subject Free Shares (SEE FOOTNOTE (2) FOR CONTINUATION OF EXPLANATION)

F2 · shares: (or 52,700 Subject Free Shares) (the "First Tranche Shares") in exchange for a cash payment of 111,724 euros, or approximately 2.12 euros per First Tranche Share. The Reporting Person's exercise of his Free Shares Put Option with respect to the First Tranche Shares for cash is deemed, for reporting purposes, to involve the conversion of the First Tranche Shares into shares of the Issuer's common stock and the simultaneous disposition of such common stock to the Issuer for cash. The August 12, 2019 euro to U.S. dollar exchange rate of 1.1194 was used for purposes of reporting the exercise price and the number of shares of the Issuer's common stock that was deemed to have been acquired and simultaneously disposed of by the Reporting Person upon exercise.

F1 · price: In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) ("Sangamo France"), the Reporting Person was granted the right to sell to the Issuer up to 238,100 "free shares" of Sangamo France (the "Subject Free Shares") for cash in four separate tranches beginning July 4, 2019 (the "Free Shares Put Options"). The exercise price per Subject Free Share to be paid by the Issuer upon the Reporting Person's exercise of its Free Shares Put Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Reporting Person notifies the Issuer of its exercise of its Free Shares Put Options (as converted to euros) divided by 12.8329. On August 12, 2019, the Reporting Person exercised his Free Shares Put Option with respect to the first tranche of Subject Free Shares (SEE FOOTNOTE (2) FOR CONTINUATION OF EXPLANATION)

F2 · price: (or 52,700 Subject Free Shares) (the "First Tranche Shares") in exchange for a cash payment of 111,724 euros, or approximately 2.12 euros per First Tranche Share. The Reporting Person's exercise of his Free Shares Put Option with respect to the First Tranche Shares for cash is deemed, for reporting purposes, to involve the conversion of the First Tranche Shares into shares of the Issuer's common stock and the simultaneous disposition of such common stock to the Issuer for cash. The August 12, 2019 euro to U.S. dollar exchange rate of 1.1194 was used for purposes of reporting the exercise price and the number of shares of the Issuer's common stock that was deemed to have been acquired and simultaneously disposed of by the Reporting Person upon exercise.

SEC source: 0001209191-20-008969 · doc5.xml · derivative · entry 1

Boissel Stephane · CIK 0001755198 · EVP, Corp. Strategy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3

Underlying: Common Stock · Not disclosed shares

Expires 2019-07-03

F1 · derivative.exercise_price: In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) ("Sangamo France"), the Reporting Person granted to the Issuer, effective November 27, 2018, the right to purchase up to 238,100 "free shares" of Sangamo France (the "Subject Free Shares") for cash in four separate tranches beginning May 3, 2019 (the "Free Shares Call Options"). The exercise price per Subject Free Share to be paid by the Issuer upon any exercise of its Free Shares Call Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Issuer notifies the Reporting Person of its exercise of its Free Shares Call Options (as converted to euros) divided by 12.8329. On July 3, 2019, the Free Shares Call Option with respect to the first tranche of Subject Free Shares (or 52,700 Subject Free Shares) expired unexercised.

F1 · derivative.underlying_shares: In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) ("Sangamo France"), the Reporting Person granted to the Issuer, effective November 27, 2018, the right to purchase up to 238,100 "free shares" of Sangamo France (the "Subject Free Shares") for cash in four separate tranches beginning May 3, 2019 (the "Free Shares Call Options"). The exercise price per Subject Free Share to be paid by the Issuer upon any exercise of its Free Shares Call Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Issuer notifies the Reporting Person of its exercise of its Free Shares Call Options (as converted to euros) divided by 12.8329. On July 3, 2019, the Free Shares Call Option with respect to the first tranche of Subject Free Shares (or 52,700 Subject Free Shares) expired unexercised.

SEC source: 0001209191-19-036443 · doc4.xml · derivative · entry 2

Smith Karen L. · CIK 0001639637 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2029-06-09

F3 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date.

SEC source: 0001209191-19-036443 · doc4.xml · nonDerivative · entry 1

Smith Karen L. · CIK 0001639637 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to the 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.

F2 · balance_after: Includes 5,000 shares of common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person on June 26, 2018. The RSUs will vest with respect to 1/3rd of the shares in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.

SEC source: 0001209191-19-036449 · doc4.xml · derivative · entry 2

Zakrzewski Joseph S · CIK 0001331852 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2029-06-09

F2 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date.

SEC source: 0001209191-19-036449 · doc4.xml · nonDerivative · entry 1

Zakrzewski Joseph S · CIK 0001331852 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to the 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.

SEC source: 0001209191-19-036442 · doc4.xml · derivative · entry 2

Ramasastry Saira · CIK 0001547959 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2029-06-09

F2 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date.

SEC source: 0001209191-19-036442 · doc4.xml · nonDerivative · entry 1

Ramasastry Saira · CIK 0001547959 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to the 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.

SEC source: 0001209191-19-036441 · doc4.xml · derivative · entry 2

PARKER H STEWART · CIK 0001217456 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2029-06-09

F2 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date.

SEC source: 0001209191-19-036441 · doc4.xml · nonDerivative · entry 1

PARKER H STEWART · CIK 0001217456 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to the 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.

SEC source: 0001209191-19-036440 · doc4.xml · derivative · entry 2

DILLY STEPHEN GEORGE · CIK 0001389147 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2029-06-09

F2 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date.

SEC source: 0001209191-19-036440 · doc4.xml · nonDerivative · entry 1

DILLY STEPHEN GEORGE · CIK 0001389147 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to the 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.

SEC source: 0001209191-19-036434 · doc4.xml · derivative · entry 2

Carey Robert · CIK 0001602064 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2029-06-09

F2 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date.

SEC source: 0001209191-19-036434 · doc4.xml · nonDerivative · entry 1

Carey Robert · CIK 0001602064 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to the 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.

SEC source: 0001209191-19-031065 · doc4.xml · derivative · entry 3

Yi Kathy · CIK 0001697802 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 5,000 shares

Expires 2027-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from February 27, 2017, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.

SEC source: 0001209191-19-031065 · doc4.xml · nonDerivative · entry 2

Yi Kathy · CIK 0001697802 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,512

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017.

F2 · balance_after: Includes 4,833 shares subject to restricted stock units granted on January 24, 2018 that will vest in two (2) remaining equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates. Additionally, this amount includes 19,250 shares subject to restricted stock units granted on February 25, 2019 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates.

SEC source: 0001209191-19-031065 · doc4.xml · nonDerivative · entry 1

Yi Kathy · CIK 0001697802 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,512

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-19-024836 · doc4.xml · derivative · entry 3

Yi Kathy · CIK 0001697802 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Common Stock · 5,000 shares

Expires 2027-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from February 27, 2017, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.

SEC source: 0001209191-19-024836 · doc4.xml · nonDerivative · entry 2

Yi Kathy · CIK 0001697802 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,512

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017.

F2 · balance_after: Includes 4,833 shares subject to restricted stock units granted on January 24, 2018 that will vest in two (2) remaining equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates. Additionally, this amount includes 19,250 shares subject to restricted stock units granted on February 25, 2019 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates.

SEC source: 0001209191-19-024836 · doc4.xml · nonDerivative · entry 1

Yi Kathy · CIK 0001697802 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,512

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-19-020126 · doc4.xml · derivative · entry 3

Yi Kathy · CIK 0001697802 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,000

Underlying: Common Stock · 5,000 shares

Expires 2027-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from February 27, 2017, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.

SEC source: 0001209191-19-020126 · doc4.xml · nonDerivative · entry 2

Yi Kathy · CIK 0001697802 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,512

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017.

F2 · balance_after: Includes 4,833 shares subject to restricted stock units granted on January 24, 2018 that will vest in two (2) remaining equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates. Additionally, this amount includes 19,250 shares subject to restricted stock units granted on February 25, 2019 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such dates.

SEC source: 0001209191-19-020126 · doc4.xml · nonDerivative · entry 1

Yi Kathy · CIK 0001697802 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,512

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.